# Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

> **NCT04440267** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Acute Leukemia of Ambiguous Lineage

## Interventions

- **DRUG:** vincristine
- **DRUG:** daunorubicin
- **DRUG:** cyclophosphamide
- **DRUG:** L-Asparaginase
- **DRUG:** prednisone
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** dexamethasone
- **DRUG:** Tyrosine kinase inhibitor

## Key facts

- **NCT ID:** NCT04440267
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-08
- **Primary completion:** 2026-06-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04440267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04440267, "Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04440267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*